Abstract
Functional PET imaging using a PARP inhibitor (PARPi) analog may serve as an early, dynamic biomarker of response to PARPi therapy in high-grade serous ovarian cancer. Clinically, this could help to rapidly identify PARPi nonresponders, thereby maximizing efficacy and avoiding toxicities of futile treatments. See related article by Pantel et al., p. 1515.
©2023 American Association for Cancer Research.
Publication types
-
Editorial
-
Research Support, N.I.H., Extramural
-
Comment
MeSH terms
-
Antineoplastic Agents* / therapeutic use
-
Biomarkers
-
Female
-
Humans
-
Ovarian Neoplasms* / diagnostic imaging
-
Ovarian Neoplasms* / drug therapy
-
Pilot Projects
-
Poly(ADP-ribose) Polymerase Inhibitors / pharmacology
-
Poly(ADP-ribose) Polymerase Inhibitors / therapeutic use
Substances
-
Poly(ADP-ribose) Polymerase Inhibitors
-
Antineoplastic Agents
-
Biomarkers